Novogene, AITbiotech Collaborate
News Sep 08, 2016
Novogene Corporation Ltd has announced a joint venture with AITbiotech Pte Ltd to establish a high-throughput (HTP) next-generation sequencing and R&D Centre in Singapore. The Singapore center, NovogeneAIT Genomics Singapore, will deliver NGS services using Illumina’s latest HiSeq X Ten sequencing system. NovogeneAIT Genomics Singapore, which will include a team of NGS professionals highly skilled in both wet-lab and bioinformatics, will provide cutting edge NGS and research services to the Association of Southeast Asian Nation (ASEAN) and South Asia region.
Under the joint venture, Novogene will invest in research and development of next-generation genetic testing products and services, especially in oncology. NovogeneAIT Genomics Singapore will embark on research and development collaborations with leading research institutes in Singapore. It is presently in discussions with such institutes and expects to announce initial collaborations in the near future, including a couple of large projects with a research entity in Singapore for the sequencing of whole human genomes.
“I am very excited and pleased to announce this significant joint venture and the formation of NovogeneAIT Genomics Singapore,” stated Dr. Ruiqiang Li, CEO of Novogene Corporation. “Our joint venture with AITbiotech represents a key milestone in Novogene’s strategy to become a truly global high-throughput next-generation sequencing services provider. With the addition of this center, we will now have three HTP NGS centers around the world, including China and the U.S.” “We are extremely excited about the opportunity to work with a leading high-throughput next-generation sequencing services company like Novogene,” said Alex Thian, AITbiotech CEO.
“AITbiotech sees this joint venture as a model of collaboration between a global company and a smaller local enterprise to jointly penetrate the large, complex ASEAN and South Asian scientific services and diagnostics markets. Our locally based technical and business expertise, as well as our established relationships in the region, will help Novogene optimize its investment and expedite business development for NovogeneAIT Genomics Singapore. This investment will be an important addition to the genomics research infrastructure in Singapore. It will help to accelerate and increase the scope of genomics data generation by public research institutions in a very significant manner.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.